Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.
Gonzalez-Robles C, Weil RS, van Wamelen D, Bartlett M, Burnell M, Clarke CS, Hu MT, Huxford B, Jha A, Lambert C, Lawton M, Mills G, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, Williams-Gray CH, Zeissler ML, Zetterberg H, Carroll CB, Foltynie T, Schrag A; EJS ACT-PD Consortium. Gonzalez-Robles C, et al. Among authors: siu c. J Parkinsons Dis. 2023;13(6):1011-1033. doi: 10.3233/JPD-230051. J Parkinsons Dis. 2023. PMID: 37545260 Free PMC article. Clinical Trial.
Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
Gonzalez-Robles C, Bartlett M, Burnell M, Clarke CS, Haar S, Hu MT, Huxford B, Jha A, Lawton M, Noyce A, Piccini P, Pushparatnam K, Rochester L, Siu C, van Wamelen D, Williams-Gray CH, Zeissler ML, Zetterberg H, Carroll CB, Foltynie T, Weil RS, Schrag A; EJS ACT-PD Consortium. Gonzalez-Robles C, et al. Among authors: siu c. Mov Disord. 2024 Feb;39(2):433-438. doi: 10.1002/mds.29691. Epub 2023 Dec 22. Mov Disord. 2024. PMID: 38140767
Patient and Public Involvement and Engagement in the Development of a Platform Clinical Trial for Parkinson's Disease: An Evaluation Protocol.
Zeissler ML, Bakshi N, Bartlett M, Batla A, Byrom D, Chapman R, Collins S, Cowd E, Deeson E, Ellis-Doyle R, Forbes J, Gonzalez-Robles C, Jewell A, Lane EL, LaPelle NR, Martin K, Matthews H, Miller L, Mills G, Morgan A, Parry M, Pushparatnam K, Ratcliffe N, Salathiel D, Scurfield P, Siu C, Whipps S, Wonnacott S, Foltynie T, Carroll CB, McFarthing K; EJS ACT-PD consortium. Zeissler ML, et al. Among authors: siu c. J Parkinsons Dis. 2024 Apr 27. doi: 10.3233/JPD-230444. Online ahead of print. J Parkinsons Dis. 2024. PMID: 38701161
Patient Experience in Early-Stage Parkinson's Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment.
Morel T, Cleanthous S, Andrejack J, Barker RA, Blavat G, Brooks W, Burns P, Cano S, Gallagher C, Gosden L, Siu C, Slagle AF, Trenam K, Boroojerdi B, Ratcliffe N, Schroeder K. Morel T, et al. Among authors: siu c. Neurol Ther. 2022 Sep;11(3):1319-1340. doi: 10.1007/s40120-022-00375-3. Epub 2022 Jul 1. Neurol Ther. 2022. PMID: 35778541 Free PMC article.
Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson's.
Morel T, Cleanthous S, Andrejack J, Barker RA, Biagioni M, Blavat G, Bloem BR, Boroojerdi B, Brooks W, Burns P, Cano S, Gallagher C, Gosden L, Siu C, Slagle AF, Ratcliffe N, Schroeder K. Morel T, et al. Among authors: siu c. J Patient Rep Outcomes. 2023 Apr 20;7(1):40. doi: 10.1186/s41687-023-00577-9. J Patient Rep Outcomes. 2023. PMID: 37079119 Free PMC article.
Antibody drug conjugates: Design implications for clinicians.
Pang S, Duong A, Siu C, Indorf A. Pang S, et al. Among authors: siu c. J Oncol Pharm Pract. 2024 Apr 23:10781552241228827. doi: 10.1177/10781552241228827. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38651308 Review.
662 results